The influence of teriparatide in induced tooth movement: a systematic review by Souza-Silva, Bianca Núbia et al.
J Clin Exp Dent. 2016;8(5):e615-21.                                                                                                                                                               The teriparatide in induced tooth movement
e615
Journal section: Oral Medicine and Pathology                            
Publication Types: Review
The influence of teriparatide in induced tooth movement: A systematic review
Bianca-Núbia Souza-Silva 1, José-Lucas-Sani-de Alcântara Rodrigues 1, Jefferson-Chaves Moreira 1, Felipe-
de Souza Matos 2, Carla-Patrícia-Hernandez-Alves-Ribeiro Cesar 3, Carlos-Eduardo-Palanch Repeke 4, Luiz-
Renato Paranhos 4
1 Undergraduate student, Department of Dentistry, Federal University of Sergipe, Lagarto, SE, Brazil
2 DDS, MSc, Postgraduate Program in Dentistry, Federal University of Sergipe, Aracaju, SE, Brazil
3 DDS, MSc, PhD, Professor, Department of Speech Therapy, Federal University of Sergipe, Lagarto, SE, Brazil
4 DDS, MSc, PhD, Professor, Department of Dentistry, Federal University of Sergipe, Lagarto, SE, Brazil
Correspondence:
Residencial Vista do Atlântico
Ap. 1402, Jordão de Oliveira st., 996
Atalaia, Aracaju/SE. ZIPCODE: 49037-330
paranhos@ortodontista.com.br
Received: 24/01/2016
Accepted: 07/04/2016
Abstract 
Background: Teriparatide is a synthetic drug similar than PTH (parathyroid hormone), which is currently used as 
long-term treatment option for patients with bone chronic diseases, as osteoporosis; and this drug can interfere in a 
positive way in orthodontic movement. 
Objectives: The medical literature was assessed in the present systematic review in order to determine the level of 
scientific evidence supporting the influence of teriparatide in induced tooth movement. 
Material and Methods: The PRISMA Checklist was followed in this systematic review. Four electronic databases 
(PubMed; Scopus; ScienceDirect; OpenGrey) were searched without implementing restrictions of year, status, and 
language of publications. The inclusion criteria consisted of selecting only experimental studies comparing the 
influence of teriparatide in tooth movement of male Wistar rats. The exclusion criteria consisted of experiments 
with female rats or other experimental animals, and animals with pathologic conditions. The eligible studies were 
evaluated based on methodological quality. Two trained examiners performed all the research steps. 
Results: The initial sample comprised 700 studies, which was reduced to 664 after the exclusion of duplicates 
(n=36). Three articles were selected for the final qualitative analysis. The local administration of parathyroid hor-
mone (PTH) 1-34 or PTH 1-84 revealed major effectiveness when compared with control groups and systematic 
administration. Additionally, the dilution of PTH 1-34 within methyl cellulose (MC) gel increased the time range 
for drug release, enabling to reduce the drug concentration without decreasing the effectiveness of tooth move-
ment.
Conclusions: Teriparatide demonstrated potential acceleration of tooth movement in Wistar rats depending on the 
drug concentration; drug administration; and time for drug release.
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Introduction
Life expectation considerably increased in the last de-
cades, changing social lifestyle and personal health ha-
bits. Consequently, adult patients became more aware 
of oral health care, boosting the demand for orthodontic 
treatment. In this way, orthodontic clinics started treating 
a population of patients with heterogeneous age range. 
In addition, these patients have different genetic profile 
and health status, which potentially interfere within the 
time and efficiency of tooth movement (1,2).
Basically, orthodontic movement is founded on the appli-
cation of vector forces in the teeth, generating two opposite 
responses in different areas of periodontal ligament. The 
first consists of pressure, which we observe an aseptic infla-
mmatory response triggering the activation of osteoclasts 
and bone resorption. The second consists of tension, which 
is generated an anti-inflammatory environment conducive 
to activation of osteoblasts and bone formation (2-4).
Therefore, systemic bone diseases may interfere within 
orthodontic treatment culminating in adverse biological 
response during tooth movement, directly influencing 
the treatment outcomes. Osteoporosis emerges as one 
of the most prevalent bone diseases in adults, affecting 
more than 75 million people worldwide, causing the 
reduction of bone density due to excessive osteoclastic 
activity (5). Currently, the long-term administration of 
teriparatide, a synthetic form of PTH, in low doses re-
presents one of the treatment options for osteoporosis. 
Paradoxically, the same PTH, which in high concentra-
tions may culminate within osteoporosis, may also en-
hance the longevity of osteoblasts, increasing the bone 
density through the elevation of bone turnover (6-9).
The hypothesis that improved bone responses, and pos-
sibly tooth movement, are achieved in patients under-
going treatment with Teriparatide was raised (10-12) 
resulting in controversial opinions among researchers 
in the field. Thus, the present systematic review aims to 
analyze the influence of teriparatide administration in 
the induced tooth movement.
Material and Methods
- Protocol and registration:
This systematic review was done adhering to the Pre-
ferred Reporting Items for Systematic Reviews and 
Meta-Analyses PRISMA (13) checklist (www.prisma-
statement.org). We did not register a protocol.
- Focused question:
The present research aimed to answer the following gui-
ding question: Is the teriparatide administration optima-
lly influencing induced tooth movement?
The research question was based on the PVO strategy 
for Systematic Exploratory Review, where P stands for 
population, context, and/or problem-situation, V stands 
for variables, and O stands for desirable or undesirable 
outcomes.
- Eligibility criteria:
• Inclusion criteria: Experimental studies comparing the 
influence of teriparatide on tooth movement in Wistar 
rats. With no restrictions on year, publication status, or 
language.
• Exclusion criteria: Articles that investigated the teri-
paratide effect on another experimental animal; female 
rats; and animals with pathologic conditions. 
- Information sources:
 A systematic search was performed in PubMed®, Sco-
pus®, ScienceDirect® and OpenGrey® electronic data-
bases. The data base OpenGrey® was used to check the 
gray literature and avoid selection bias.
- Search:
Medical Subject Headings (MeSH) and boolean opera-
tors (“OR” / “AND”) were used to build a search string 
with the terms “Teriparatide”, “Orthodontic” and “Pa-
rathyroid Hormone”. The search strategy (Table 1) was 
performed in May 14th 2015.
 The results obtained were exported to the software 
Mendeley Desktop 1.13.3 (Mendeley™ Ltd, London, 
UK), where duplicity was verified.
- Study selection: 
Selection was completed in 2 phases. Titles and abstracts 
were systematically assessed by two reviewers for eli-
gibility (JLSAR and BNSS), and they were not blind to 
authors or journals. Whenever the title and abstract of ar-
ticles did not present enough information, full texts were 
obtained and analyzed to decide on their eligibility. Arti-
cles presenting a title that fit the theme but with no availa-
ble abstracts, were also obtained and fully analyzed. 
The full texts of previously eligible articles were down-
loaded and read so to verify the presence of every inclu-
sion criteria. In specific cases, the authors of potentially 
eligible articles were contacted by e-mail and asked for 
missing information. The rejected articles were registe-
red separately, displaying the reasons for exclusion.
- Data collection process: 
Two examiners assessed the risk of bias and quality in 
individual studies (JLSAR and BNSS). In case of disa-
greement, a third examiner (LRP) was consulted. At this 
point, the review was blindly performed, masking the 
names of authors and journals, avoiding any potential 
bias and conflicts of interests during sample selection.
- Data items:
After triage, the full texts of pre-selected articles were 
re-examined and their data were extracted in a standar-
dized manner. The information extracted and recorded 
from the articles were authorship; year and place of pu-
blication; sample profile; orthodontic technique; drug 
administration; tooth movement rate in experimental 
and control groups; and clinical outcome.
- Risk of bias in individual studies:
The selected studies assessed the risk of bias and quality 
in individual studies using a standard checklist (Table 2). 
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Database Search strategy
Total
Key words
PubMed
www.ncbi.nlm.nih.gov/pubmed/
(“teriparatide”[MeSH Terms] OR “teriparatide”[All Fields]) AND 
orthodontic[All Fields]
1
(“parathyroid hormone”[MeSH Terms] OR (“parathyroid”[All Fields] 
AND “hormone”[All Fields]) OR “parathyroid hormone”[All Fields]) AND 
orthodontic[All Fields]
23
Scopus
www.scopus.com
“teriparatide” AND “orthodontic” 1
“parathyroid hormone” OR “parathyroid” AND “hormone” AND 
“orthodontic”
26
ScienceDirect
www.sciencedirect.com
“teriparatide” AND “orthodontic” 32
“parathyroid hormone” OR “parathyroid” AND “hormone” AND “orth-
odontic”
570
OpenGrey
http://www.opengrey.eu/
“teriparatide” AND “orthodontic” 0
“parathyroid hormone” OR “parathyroid” AND “hormone” AND 
“orthodontic”
47
Total 700
Table 1. Electronic databases and applied search strategy.
Each study received a score adapted from Cericato et al. 
(14): low quality study (from 0 to 5 points); average quality 
(from 6 to 9 points); high quality (from 10 to 12 points).
- Summary measures:
The process of data synthesis was performed through a 
descriptive analysis of the selected studies, and the final 
product of the analysis was presented in narration/dis-
sertation form.
- Synthesis of results:
The process of data synthesis was performed through a 
descriptive analysis of the selected studies, and the final 
Selection criteria Score
1. The abstract presents the research aims, methodology, results and discussion. 1 point
2. The research clearly presents the results. 1 point
3. The ethical aspects are reported. 1 point
4. The research design is properly specified (information on the type of study, inclusion and exclusion 
criteria, control groups, and randomization are reported).
3 points
5. The sample size determination is described. 2 points
6. The statistic methodology is reported, including the p value. 2 points
7. The research aims and results are clearly reported. 1 point
8. The research limitations are reported. 1 point
Table 2. Scores and selection criteria adapted from Cericato et al. (14).
product of the analysis was presented in narration/dis-
sertation form. A meta-analysis was planned, since the 
data from the included studies was considered relatively 
homogeneous.
- Risk of bias across studies:
Only to be applied if meta-analysis was possible.
Results
- Study selection:
A flowchart describing the process of identification, in-
clusion, and exclusion of studies is shown in figure 1. A 
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Fig. 1. Flow diagram of literature search and selection criteria adapted from PRISMA.
total of 700 results were retrieved during the first selec-
tion phase; after removing duplicates, the total was 664 
results. After applying inclusion and exclusion criteria, 
three articles remained eligible. 
- Study characteristics:
Two eligible studies (10,11) were published in Japan, 
while one Li et al. (12) was published in China. All the 
studies were published in English language between 
1999 and 2013.
- Risk of bias within studies:
All the studies reached at least average scores based 
on previous evaluation (Table 2). Some aspects beca-
me specifically evident, such as the lack of sample size 
calculation in the three eligible articles, and the lack of 
discussion on the study limitations in one eligible article 
(11).
- Results of individual studies:
Soma et al. (11) injected subcutaneous PTH 1-34 and 
PTH 1-84 in 112 Wistar rats, in a daily basis, with con-
centration varying between 0.4-4.0 µg/100 g (PTH 1-34) 
and 10 µg/100 g (PTH 1-84). A second group received 
PTH 1-34 with concentration of 4.0 µg/100 g on the dor-
sal region of the animal. Control group did not receive 
PTH (Table 3).
Soma et al. (11) injected PTH 1-134 diluted within me-
thyl cellulose gel 2%w/v in the mesiopalatal region of 
the maxillary first molar of 56 Wistar rates, with inters-
persed applications (every other day). Additional appli-
cations consisted of local injections of non-diluted PTH 
1-34; and subcutaneous injection of PTH 1-34 concen-
trated in 1.0 µg/400 g on the dorsal region of the animal. 
All the animals underwent orthodontic force of 30g (Ta-
ble 3). 
Li et al. (12) injected subcutaneous PTH 1-34 diluted 
within a buffered phosphate solution in 60 Wistar rats, 
with concentration of 4.0 µg/100 g. A control group was 
treated without the injection of PTH. All the rats un-
derwent orthodontic force of 40 g (Table 3). 
In all the studies PTH 1-84 or PTH 1-34, also known as 
teriparatide, was injected in the moment “0” (day 0), and 
the closed coil spring was installed between the maxi-
llary right first molar and the incisors. The activation of 
these orthodontic appliances was performed immedia-
tely after installation (day 1). No further reactivation was 
performed (10-12). The Wistar rats underwent euthana-
sia in experiment day 0 (before orthodontic movement), 
3, 6, 9, 12 (10-12). Yet Soma et al. (11) designed a triple 
measurement methodology performed by three blind 
examiners (Table 3).  
- Synthesis of results:
Soma et al. (10) examined the tooth movement using a 
microscope at a magnification of 40 x aided by calipers 
with precision of 0.05mm.11 Similarly, Soma et al. (11) 
and Li et al. (12), used digital calipers with precision of 
0.05mm and 0.02mm respectively.
Soma et al. (10) revealed that daily injections of subcuta-
neous PTH 1-84 with concentration of 1.3 and 10 µg/100 
g significantly increased the number of osteoclasts in the 
region of pressure after 72 hours of applied orthodontic 
force. However, effects on tooth movement were only 
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
Authors
and year  
Country Sample 
(n) Weight
Control
group
Orthodontic
technique 
Drug
administration
Drug
concentration 
Clinical outcome 
Soma et al. (10) 1999 Japan 40 ƃ 
 
350-
400g 
Yes Closed coil 
spring with 
force of 30g 
Daily 
subcutaneous 
injection 
PTH 1-34 at 
0.4 and 
4µg/100g  
 Tooth movement was 
statistically significant 
comparing the group 
receiving PTH 1-84 at 
10µg/100g and PTH 1-34 
at 4µg/100 with the 
control group along 6, 9 
and 12 days after the 
application of orthodontic 
force. 
Daily 
subcutaneous 
injection 
PTH 1-84 at 
10µg/100g  
Injection in the 
dorsal back 
region 
PTH 1-34 at 
4µg/100g   
Soma  et al. (11) 2000 Japan 
 
56 ƃ 
 
350–
380g 
Yes Closed coil 
spring with 
force of 30g 
Injection 
diluted within 
MC gel in 
interspersed 
days 
  PTH 1-34 at 
1µg/400g  
 Tooth movement was 
statistically significant 
comparing the group 
receiving 1µg of PTH with 
the control group (without 
PTH), and with the 
systemic and local 
injection of PTH without 
MC gel along 6, 9 and 12 
days after the application 
of orthodontic force. 
Injection 
diluted within 
MC gel in 
interspersed 
days 
PTH 1-34 at 
0.1µg/400g  
Local injection 
diluted with 
MC gel 
PTH 1-34 at 
1µg/400g  
Li  et al. (12) 2013 China 
 
60 ƃ 
 
190-
210g 
Yes Closed coil 
spring with 
force of 40g 
Intermittent 
injection 
 
PTH 1-34 at 
4µg /100g 
Tooth movement was 
statistically significant 9 days 
after the application of 
orthodontic force. 
Ostoeclclastic cells were 
observed in the 3rd day, and 
increased in the 6th and 9th 
days. 
Table 3. Summary of study descriptive characteristics of included studies.
observed with PTH concentration of 10 µg/100 g. Addi-
tionally, the authors compared the findings observed 
within 0, 3, 6, 9, and 12 days after the application of 
orthodontic force with subcutaneous injection of PTH 
1-84 at 10 µg/100 g and PTH 1-34 at 0.4 and 4 µg/100 
g; as well as dorsal injection of PTH-134 at 4 µg/100 
g. The groups receiving PTH 1-84 at 10 µg/100 g and 
PTH 1-34 at 4 µg/100 g presented tooth movement rates 
approximately 3 times higher if compared with the con-
trol group 6, 9 and 12 days after the application of or-
thodontic force. On the other hand, even in the absence 
of significant tooth movement, the daily dorsal injection 
of PTH 1-34 at 4 µg/100 g revealed systemic alterations 
in the sample, such as increased bone mineral density, 
and phosphorus and alkaline phosphatase (ALP) serum 
levels (10).  
In this way, Soma et al. (11) decreased the concentration 
and increased the release time of PTH combining the 
drug with methyl cellulose gel in local injections. Con-
sequently, the authors observed that PTH with concen-
tration level set at 1 µg/per animal presented significant 
improvement in tooth movement, within interspersed 
applications, if compared to any other group (11).
Yet Li et al. (12) used a higher concentration of PTH 
1-34 (4 µg/100 g) and orthodontic force (40 g) in rats 
with lighter weight. Tooth movement was significantly 
higher 9 days after the application of orthodontic force. 
Additionally, the authors observed a major concentra-
tion of osteoclasts; tartrate-resistant acid phosphatase 
(TRAP) positive cells, receptor activator of nuclear fac-
tor kappa-B (RANKL); and insulin grown factor (IGF)-1 
in periodontal region of pressure (12)
- Risk of bias across studies:
The scientific articles selected did not have compatible 
results that would allow a meta-analysis, since they were 
heterogenous. Furthermore, a meta-analysis could not be 
done due to lack of clinical studies on this topic.
Discussion
Orthodontic tooth movement includes two main biolo-
gical responses – bone resorption and formation (3,4). 
Interestingly the same degree of force, but with the 
opposite direction results in different effects on perio-
dontal ligament cells. The bone region under pressure 
has predominant expression of pro inflammatory cyto-
kines and chemokines, such as tumor necrosis factor 
(TNF)-α and Interleukin (IL)-1β (3). This physiological 
environment enables the activation of osteoclasts, which 
are mediators for the response of bone resorption. In fact, 
the predominant expression of pro inflammatory media-
tors directly increases the concentration of specific cell 
types, such as monocytes/macrogaphages, which pre-
cedes the osteoclast formation (3,15,16). Additionally, 
the presence of cytokines TNF-α and IL-1β are strictly 
associated with the expression of the main osteoclasto-
genic components – the RANK/RANKL system (15). 
Specifically, RANKL is linked to the receptor RANK in 
pre-osteoclastic (monocytes) cells generating intracellu-
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lar signal through nuclear factor kappa B (NFkB) and 
AP-1; transcription factors for osteoclastic formation 
and activation; and consequent local bone resorption 
(17,18). Oppositely, the bone region under tension re-
veals an anti-inflammatory environment, with prevalent 
expression of anti-inflammatory cytokines, such as IL-
10; and transforming growth factor (TGF)-β (3). IL-10 
and TGF-β negatively interfere within the expression of 
TNF-α and IL-1β; increases the expression of osteopro-
tegerine (OPG) – a decoy of RANK that decreases the 
RANK/RANKL binding; and consequently avoids the 
osteoclasts formation (15,17,18). 
Once the orthodontic movement presents two comple-
tely different environments, the discovery and/or ad-
ministration of a drug that accelerates or increase the 
effectiveness of bone resorption and formation at the 
same time becomes extremely difficult. In fact, a sys-
temic drug which increases the rate of bone resorption 
by osteoclasts, possibly interfere negatively on bone for-
mation by osteoblasts on the opposite side of the tooth. 
Similarly, agents that promote bone formation possibly 
reduce the handling time for interfering with the absorp-
tion area of the pressure side.
Teriparatide arose as a systemic synthetic drug with 
the same amino acid sequence of the PTH active form, 
which is currently used as long-term treatment option 
for patients with osteoporosis; and this drug can interfe-
re in a positive way in both sides (pressure and tension 
area). In the tension area, Teriparatide is linked to the 
PTH receptor identified in osteoblasts and related pre-
ceding cells – pluripotent progenitors of mesenchymal 
lineage (19). Thus, the main intracellular mechanism of 
activity of Teriparatide in the osteoblasts occurs from 
its interaction with the specific receptor type I (PRPI), 
which is attached to the G protein (8). In the bone re-
gion under tension, anabolic bone effects are observed. 
Mainly, these effects are associated with the link bet-
ween Teriparatide and PRPI attached to Gq protein, 
which activates kinase C, controlling the formation of 
growth factors (IGF-I, IGF-II e TGF-β) and indirectly 
increasing the expression of OPG (inhibiting osteoclast 
formation). Optionally, Teriparatide may also link with 
PRPI receptor and stimulate adenil-ciclase in osteoblasts 
(main structures for RANKL production), increasing the 
concentration of cyclic AMP and activating protein-ki-
nase A (PKA) associated to the secretion of IL-6 and de 
RANKL – chain factors for bone resorption (8). Thus, 
Teriparatide may enhance bone turnover and interferes 
within the time for orthodontic tooth movement main-
taining quality after bone formation response. Based on 
that, Teriparatide may potentially optimize both the bone 
response for resorption and formation (2,8,16).
Despite the apparent benefits of Teriparatide, effective 
tooth movement depends on the type of drug adminis-
tration and concentration (10,12). Specifically in or-
thodontics, direct effect of Teriparatide in osteoblasts is 
expected. Based on that, local drug injection is the best 
approach once systemic administration may spread the 
drug to different body region decreasing the drug con-
centration in the bone adjacent to the teeth under mo-
vement. This is observed administrating subcutaneous 
PTH at 4 µg/100 g on the back region of Wistar rats 
and comparing with controlled rats under orthodontic 
treatment (10). Oppositely, a higher dose of PTH (10 
µg/100 g) improved the tooth movement if compared 
with the control group (10). It may indicate that hig-
her drug concentration within systemic administration 
provides major remaining dose in the bone adjacent to 
the teeth under movement (10). Additionally, the higher 
drug dose increased the number of osteoclasts in region 
under pressure and decreased the time for bone resorp-
tion, avoiding local necrosis (10).
Apparently, PTH must be chronically administrated 
for a proper effectiveness within tooth movement, fo-
llowing local application with ideal quantity. Several 
other drugs that require similar conditions were tested 
for application diluted within drug carriers and other 
substances to increase the drug half-life in the anatomic 
site of interest. In fact, the local and systemic adminis-
tration of PTH with concentration of 1 µg/400 g did not 
result with statistically significant tooth movement (11). 
However, the same local (periodontal region) drug set 
up diluted within MC increased the tooth movement rate 
2x if compared to the group of receiving PTH diluted in 
saline (11). Methyl-cellulose gel is already used com-
bined with lidocaine to enhance nerve blocking during 
anesthetic interventions, without revealing side effects 
(20). Based on that, this gel has the capacity to decrease 
the drug release in the anatomic site of application, ma-
king it available for a longer period within low quantity, 
which is an ideal condition for the chronic administra-
tion of PTH aiming tooth movement (8).
Local concentration and the period of drug released are 
apparently important factors affecting its effectiveness 
in tooth movement. Additionally, the size of the protein 
also seems to influence the outcomes. Despite the fact 
that Teriparatide has the same effect of PTH (with 34 ac-
tive amino acids present in the hormone), it has a smaller 
structure, which may present differences found within 
the experimental models of orthodontic movement, cau-
sing confusion and divergence in the current literature. 
The administration of systemic PTH with concentration 
of 4 µg/100 g on a daily basis, in rats weighting 350-
400 g, resulted within an increasing amount of serum 
markers for bone apposition and mineral bone density, 
but not on tooth movement acceleration (10). Yet the Te-
riparatide systemically administrated with concentration 
of 4 µg/100 g every other day, in rats weighting approxi-
mately 200g, resulted within improved tooth movement 
and increased amount of RANKL+ and TRAP+ cells in 
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the bone region under pressure, as well as higher po-
sitivity for OPG and IGF-1 when compared to control 
groups, indicating a high expression of osteoclastoge-
nic and bone formation factors. Once Teriparatide is 
structurally smaller than PTH, it may maintain a higher 
concentration in the periodontal region or even major in 
vivo affinity with PTH receptors in the osteoblasts of the 
periodontal ligament. Further studies on the affinity to 
PTH receptors and its activation are encouraged consi-
dering that Teriparatide and PTH may present a different 
activation of PTK, triggering different intracellular sig-
naling with opposite effects.     
Despite complex and paradoxical, the administration of 
Teriparatide and even PTH in experiments involving in-
duced tooth movement in rats may influence on tooth 
movement acceleration depending on the drug adminis-
tration (local/systemic) and time of release, concentra-
tion and periodicity (10-12). Evidently, additional re-
searches remain necessary to elucidate the mechanism 
of Teriparatide interaction with bone apposition and re-
sorption within tooth movement in humans. However, 
considering the chronic administration of Teriparatide in 
low concentration doses in patients with osteoporosis, 
and even the individual genetic profile and pathologies, 
which cause different concentrations on the physiologi-
cal production of PTH production, orthodontic patients 
may present different responses to applied forces, re-
quiring major attention of the Orthodontists in face of 
the patient’s clinical status. Additionally, Teriparatide 
revealed to be a potential option for further studies at-
tempting to improve the clinical routine of orthodontic 
mechanics. 
In this way, this systematic review concluded that there 
is evidence showing that the use of teriparatide may ac-
celerate the induced tooth movement in rats depending 
on the way of drug administration and the time for drug 
release.
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